(19)
(11) EP 3 317 279 A1

(12)

(43) Date of publication:
09.05.2018 Bulletin 2018/19

(21) Application number: 16733538.9

(22) Date of filing: 30.06.2016
(51) International Patent Classification (IPC): 
C07D 471/10(2006.01)
A61K 31/438(2006.01)
C07D 519/00(2006.01)
A61P 35/00(2006.01)
(86) International application number:
PCT/EP2016/065231
(87) International publication number:
WO 2017/005583 (12.01.2017 Gazette 2017/02)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
MA MD

(30) Priority: 03.07.2015 EP 15175259

(71) Applicant: F. Hoffmann-La Roche AG
4070 Basel (CH)

(72) Inventors:
  • BUETTELMANN, Bernd
    4070 Basel (CH)
  • KOCER, Buelent
    4070 Basel (CH)
  • KUHN, Bernd
    4070 Basel (CH)
  • PRUNOTTO, Marco
    4070 Basel (CH)
  • RICHTER, Hans
    4070 Basel (CH)
  • RITTER, Martin
    4070 Basel (CH)
  • RUDOLPH, Markus
    4070 Basel (CH)
  • SATZ, Alexander Lee
    4070 Basel (CH)

(74) Representative: Schirlin, Julien 
F. Hoffmann-La Roche AG CLP - Patent Department Grenzacherstrasse 124
4070 Basel
4070 Basel (CH)

   


(54) TRIAZA-SPIRODECANONES AS DDR1 INHIBITORS